Mirum raised its full‑year net product sales outlook to a $680‑$700 million range, reflecting a 46% jump in LIVMARLI revenue and expanding pipeline momentum. The higher target broadens upside potential while the company still posted a $‑0.80 EPS loss, keeping earnings pressure on investors.
Key Highlights
- The next FDA milestones are expected to shape the company’s near‑term market positioning.
- Investors are closely watching the regulatory timeline for potential catalytic impact.
- The next FDA milestones are expected to shape the company’s near‑term market positioning. - Investors are closely watching the regulatory timeline for potential catalytic impact.
Peers Moving on This News
- Twist Bioscience Corp (TWST) little changed
- Erasca Inc (ERAS) up 4.3%
Analysis based on the Form 8-K filed 5 August 2026.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.